Blobner M, Felber A R, Schneck H J, Jelen-Esselborn S
Institut für Anästhesiologie, Technischen Universität München, Klinikum rechts der Isar.
Anasthesiol Intensivmed Notfallmed Schmerzther. 1994 Oct;29(6):338-42. doi: 10.1055/s-2007-996755.
In patients with extreme stature or build, estimation of individual dosage requirements of muscle relaxants by body weight is unreliable. To define a more precise guideline for dosage of atracurium in clinical practice we compared in this prospective study in patients with a wide range of body weights the cumulative effective dose for a 95% twitch depression (ED95), the dosage necessary to maintain a 95% twitch depression (DD95) and the recovery from a 95% neuromuscular block with simple demographic data such as body weight, body size, body surface area and lean body mass (LBM).
30 patients were divided into three groups according to the individual body weight: underweight, normal, overweight. The electromyographic response was monitored using train-of-four stimuli applied to the ulnar nerve. Neuromuscular block was induced by constant infusion of atracurium; the dose required for a 95% twitch depression was registered as ED95. The infusion rate was then adjusted to maintain a constant electromyographic response of the first twitch of 5 +/- 1% for at least 30 minutes and the required dose of atracurium was recorded as DD95. The neuromuscular recovery was studied regarding T1 and T4-ratio. Data are given as medians (25%-/75%-quartiles).
The cumulative ED95 in underweight patients (0.34 (0.31/0.48) mg/kg) exceeded (P < 0.05) those in normal (0.29 (0.26/0.30) mg/kg) and in overweight patients (0.22 (0.18/0.26) mg/kg). In contrast to calculations according to the normal weight (Mn) no difference in ED95 was seen between groups (normal: 0.29 (0.26/0.30) mg/kg Mn; underweight: 0.28 (0.26/0.32) mg/kg Mn; overweight: 0.31 (0.25/0.32) mg/kg Mn). The individual DD95 was best correlated with LBM (r = 0.465, p < 0.01). In view of the difficulty of estimating LBM in routine clinical practice it is emphasized that DD95 correlates only slightly less with normal weight (r = 0.404, p < 0.05). In spite of the variability of DD95 with regard to body weight, the recovery of neuromuscular transmission in the patients of the three groups is comparable. As a constant neuromuscular block cannot be maintained without monitoring muscular evoked responses, even if body build is taken into account, neuromuscular monitoring is advocated for longer infusion of atracurium.
对于身材或体型极为特殊的患者,通过体重来估算肌肉松弛剂的个体剂量需求并不可靠。为了在临床实践中确定更精确的阿曲库铵剂量指南,我们在这项前瞻性研究中,比较了体重范围广泛的患者中,达到95%颤搐抑制的累积有效剂量(ED95)、维持95%颤搐抑制所需的剂量(DD95)以及从95%神经肌肉阻滞恢复的情况,并与体重、体型、体表面积和去脂体重(LBM)等简单人口统计学数据进行了比较。
30名患者根据个体体重分为三组:体重过轻、正常、超重。使用施加于尺神经的四个成串刺激来监测肌电图反应。通过持续输注阿曲库铵诱导神经肌肉阻滞;达到95%颤搐抑制所需的剂量记录为ED95。然后调整输注速率,以至少30分钟维持第一个颤搐的恒定肌电图反应为5±1%,并将所需的阿曲库铵剂量记录为DD95。研究了关于T1和T4比率的神经肌肉恢复情况。数据以中位数(25%/75%四分位数)表示。
体重过轻患者的累积ED95(0.34(0.31/0.48)mg/kg)超过(P<0.05)正常体重患者(0.29(0.26/0.30)mg/kg)和超重患者(0.22(0.18/0.26)mg/kg)。与根据正常体重(Mn)计算的结果相反,各组之间在ED95方面未观察到差异(正常:0.29(0.26/0.30)mg/kg Mn;体重过轻:0.28(0.26/0.32)mg/kg Mn;超重:0.31(0.25/0.32)mg/kg Mn)。个体DD95与LBM的相关性最佳(r = 0.465,p<0.01)。鉴于在常规临床实践中估算LBM存在困难,需要强调的是,DD95与正常体重的相关性仅略低(r = 0.404,p<0.05)。尽管DD95随体重存在变异性,但三组患者的神经肌肉传递恢复情况具有可比性。由于即使考虑体型,若不监测肌肉诱发反应就无法维持恒定的神经肌肉阻滞,因此对于较长时间输注阿曲库铵,提倡进行神经肌肉监测。